Eurofins Genomics Plans for the Expasnion of Manufacturing Facility in USA
Introduction:
Eurofins Genomics is set to expand its capabilities with the addition of a new GMP oligonucleotide manufacturing facility in the USA.
Features:
The expanded 75,000 square feet facility significantly boosts manufacturing capacity and capabilities to meet the growing global demand for GMP-grade and research-use oligonucleotides.
The facility equipped with advanced automation and process controls, enhances production efficiency, purity, and traceability—key factors for applications such as NGS adaptors and capture panels.
This state-of-the-art GMP facility, supports the production of synthetic DNA and RNA with the highest standards of quality, safety, and efficiency.
The facility features fully segregated production trains for research-use-only (RUO) and GMP products, maintaining separation from synthesis to shipping. This ensures that oligonucleotides for molecular diagnostics, therapeutics, clinical applications, and other regulated sectors are produced in a tightly controlled, high-quality environment.
Specifications:
| Name | Eurofins Genomics |
| Type | Expansion |
